annual EBITDA:
$42.61M+$108.23M(+164.94%)Summary
- As of today (September 17, 2025), FOLD annual EBITDA is $42.61 million, with the most recent change of +$108.23 million (+164.94%) on December 31, 2024.
- During the last 3 years, FOLD annual EBITDA has risen by +$236.32 million (+122.00%).
- FOLD annual EBITDA is now at all-time high.
Performance
FOLD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$5.92M+$195.00K(+3.19%)Summary
- As of today (September 17, 2025), FOLD quarterly EBITDA is -$5.92 million, with the most recent change of +$195.00 thousand (+3.19%) on June 30, 2025.
- Over the past year, FOLD quarterly EBITDA has dropped by -$23.07 million (-134.52%).
- FOLD quarterly EBITDA is now -116.91% below its all-time high of $35.01 million, reached on December 31, 2009.
Performance
FOLD quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$32.95M-$23.07M(-41.18%)Summary
- As of today (September 17, 2025), FOLD TTM EBITDA is $32.95 million, with the most recent change of -$23.07 million (-41.18%) on June 30, 2025.
- Over the past year, FOLD TTM EBITDA has increased by +$49.63 million (+297.50%).
- FOLD TTM EBITDA is now -41.18% below its all-time high of $56.02 million, reached on March 31, 2025.
Performance
FOLD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FOLD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +164.9% | -134.5% | +297.5% |
| 3 y3 years | +122.0% | +90.0% | +114.1% |
| 5 y5 years | +114.4% | +87.8% | +112.4% |
FOLD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +121.4% | -122.0% | +90.0% | -41.2% | +114.1% |
| 5 y | 5-year | at high | +114.4% | -122.0% | +91.4% | -41.2% | +112.4% |
| alltime | all time | at high | +113.3% | -116.9% | +96.2% | -41.2% | +108.8% |
FOLD EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$5.92M(-3.2%) | $32.95M(-41.2%) |
| Mar 2025 | - | -$6.12M(-133.9%) | $56.02M(+31.5%) |
| Dec 2024 | $42.61M(-164.9%) | $18.01M(-33.2%) | $42.61M(+84.6%) |
| Sep 2024 | - | $26.97M(+57.3%) | $23.09M(-238.4%) |
| Jun 2024 | - | $17.15M(-187.8%) | -$16.68M(-66.0%) |
| Mar 2024 | - | -$19.52M(+1192.8%) | -$49.02M(-25.3%) |
| Dec 2023 | -$65.62M(-67.0%) | -$1.51M(-88.2%) | -$65.62M(-36.6%) |
| Sep 2023 | - | -$12.80M(-15.7%) | -$103.54M(-15.6%) |
| Jun 2023 | - | -$15.18M(-58.0%) | -$122.73M(-26.4%) |
| Mar 2023 | - | -$36.13M(-8.4%) | -$166.71M(-16.3%) |
| Dec 2022 | -$199.08M(+2.8%) | -$39.43M(+23.3%) | -$199.08M(-12.9%) |
| Sep 2022 | - | -$31.99M(-45.9%) | -$228.54M(-2.4%) |
| Jun 2022 | - | -$59.16M(-13.6%) | -$234.15M(+10.8%) |
| Mar 2022 | - | -$68.50M(-0.6%) | -$211.23M(+9.0%) |
| Dec 2021 | -$193.71M(-17.6%) | -$68.89M(+83.3%) | -$193.71M(+3.8%) |
| Sep 2021 | - | -$37.59M(+3.7%) | -$186.64M(-5.9%) |
| Jun 2021 | - | -$36.25M(-28.9%) | -$198.28M(-5.9%) |
| Mar 2021 | - | -$50.98M(-17.5%) | -$210.63M(-10.4%) |
| Dec 2020 | -$235.01M(-20.6%) | -$61.82M(+25.6%) | -$235.01M(-9.6%) |
| Sep 2020 | - | -$49.23M(+1.3%) | -$260.05M(-2.3%) |
| Jun 2020 | - | -$48.59M(-35.5%) | -$266.22M(-9.0%) |
| Mar 2020 | - | -$75.36M(-13.2%) | -$292.42M(-1.2%) |
| Dec 2019 | -$295.96M(-7.9%) | -$86.86M(+56.8%) | -$295.96M(+6.9%) |
| Sep 2019 | - | -$55.40M(-25.9%) | -$276.78M(-26.2%) |
| Jun 2019 | - | -$74.80M(-5.2%) | -$375.19M(+8.4%) |
| Mar 2019 | - | -$78.91M(+16.6%) | -$346.05M(+7.7%) |
| Dec 2018 | -$321.26M(+61.6%) | -$67.68M(-56.0%) | -$321.26M(+1.7%) |
| Sep 2018 | - | -$153.81M(+236.9%) | -$315.85M(+46.7%) |
| Jun 2018 | - | -$45.66M(-15.6%) | -$215.25M(+0.2%) |
| Mar 2018 | - | -$54.11M(-13.1%) | -$214.79M(+3.6%) |
| Dec 2017 | -$198.79M(+20.2%) | -$62.27M(+17.0%) | -$207.29M(+8.0%) |
| Sep 2017 | - | -$53.20M(+17.7%) | -$191.99M(+2.7%) |
| Jun 2017 | - | -$45.20M(-3.0%) | -$186.93M(+4.2%) |
| Mar 2017 | - | -$46.61M(-0.8%) | -$179.31M(+4.4%) |
| Dec 2016 | -$165.32M(+36.5%) | -$46.97M(-2.4%) | -$171.82M(+4.5%) |
| Sep 2016 | - | -$48.14M(+28.1%) | -$164.37M(+9.7%) |
| Jun 2016 | - | -$37.58M(-3.9%) | -$149.77M(+8.8%) |
| Mar 2016 | - | -$39.13M(-1.0%) | -$137.70M(+13.7%) |
| Dec 2015 | -$121.11M | -$39.52M(+17.8%) | -$121.11M(+17.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$33.54M(+31.5%) | -$102.72M(+19.2%) |
| Jun 2015 | - | -$25.51M(+13.2%) | -$86.20M(+15.0%) |
| Mar 2015 | - | -$22.54M(+6.7%) | -$74.94M(+11.7%) |
| Dec 2014 | -$67.12M(+11.9%) | -$21.12M(+24.1%) | -$67.12M(+14.0%) |
| Sep 2014 | - | -$17.03M(+19.4%) | -$58.90M(+4.1%) |
| Jun 2014 | - | -$14.26M(-3.1%) | -$56.58M(-2.2%) |
| Mar 2014 | - | -$14.71M(+14.0%) | -$57.87M(-3.5%) |
| Dec 2013 | -$59.97M(+18.5%) | -$12.90M(-12.3%) | -$59.97M(-3.5%) |
| Sep 2013 | - | -$14.71M(-5.5%) | -$62.17M(-2.8%) |
| Jun 2013 | - | -$15.55M(-7.5%) | -$63.96M(+11.6%) |
| Mar 2013 | - | -$16.81M(+11.3%) | -$57.31M(+12.8%) |
| Dec 2012 | -$50.63M(+2.7%) | -$15.10M(-8.4%) | -$50.83M(+5.0%) |
| Sep 2012 | - | -$16.49M(+85.2%) | -$48.41M(+8.5%) |
| Jun 2012 | - | -$8.90M(-13.8%) | -$44.61M(-10.8%) |
| Mar 2012 | - | -$10.32M(-18.6%) | -$50.01M(+1.6%) |
| Dec 2011 | -$49.30M(-8.3%) | -$12.69M(-0.1%) | -$49.24M(-6.4%) |
| Sep 2011 | - | -$12.70M(-11.2%) | -$52.61M(-0.1%) |
| Jun 2011 | - | -$14.30M(+49.5%) | -$52.67M(+4.2%) |
| Mar 2011 | - | -$9.56M(-40.4%) | -$50.53M(-6.0%) |
| Dec 2010 | -$53.78M(+1355.1%) | -$16.05M(+25.9%) | -$53.78M(+1882.3%) |
| Sep 2010 | - | -$12.75M(+4.9%) | -$2.71M(-5.5%) |
| Jun 2010 | - | -$12.16M(-5.1%) | -$2.87M(-29.0%) |
| Mar 2010 | - | -$12.81M(-136.6%) | -$4.05M(+9.5%) |
| Dec 2009 | -$3.70M(-91.3%) | $35.01M(-371.1%) | -$3.70M(-93.0%) |
| Sep 2009 | - | -$12.91M(-3.1%) | -$53.13M(+8.1%) |
| Jun 2009 | - | -$13.33M(+7.0%) | -$49.13M(+6.9%) |
| Mar 2009 | - | -$12.46M(-13.6%) | -$45.96M(+8.2%) |
| Dec 2008 | -$42.46M(-4.7%) | -$14.42M(+61.7%) | -$42.46M(+3.0%) |
| Sep 2008 | - | -$8.92M(-12.2%) | -$41.21M(-5.9%) |
| Jun 2008 | - | -$10.16M(+13.3%) | -$43.79M(+0.4%) |
| Mar 2008 | - | -$8.97M(-31.9%) | -$43.60M(-2.2%) |
| Dec 2007 | -$44.57M(-2.9%) | -$13.17M(+14.6%) | -$44.57M(+41.9%) |
| Sep 2007 | - | -$11.49M(+15.2%) | -$31.40M(+57.7%) |
| Jun 2007 | - | -$9.97M(+0.4%) | -$19.91M(+100.4%) |
| Mar 2007 | - | -$9.93M | -$9.93M |
| Dec 2006 | -$45.91M(+123.6%) | - | - |
| Dec 2005 | -$20.53M(+144.9%) | - | - |
| Dec 2004 | -$8.38M(+54.1%) | - | - |
| Dec 2003 | -$5.44M | - | - |
FAQ
- What is Amicus Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Amicus Therapeutics, Inc.?
- What is Amicus Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Amicus Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Amicus Therapeutics, Inc.?
- What is Amicus Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Amicus Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Amicus Therapeutics, Inc.?
- What is Amicus Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Amicus Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of FOLD is $42.61M
What is the all time high annual EBITDA for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. all-time high annual EBITDA is $42.61M
What is Amicus Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, FOLD annual EBITDA has changed by +$108.23M (+164.94%)
What is Amicus Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of FOLD is -$5.92M
What is the all time high quarterly EBITDA for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. all-time high quarterly EBITDA is $35.01M
What is Amicus Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, FOLD quarterly EBITDA has changed by -$23.07M (-134.52%)
What is Amicus Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of FOLD is $32.95M
What is the all time high TTM EBITDA for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. all-time high TTM EBITDA is $56.02M
What is Amicus Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, FOLD TTM EBITDA has changed by +$49.63M (+297.50%)